Next Gen Biotech

Lenvakast 4mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment.

Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to lenvatinib or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenvakast 4mg Capsule, as it can impair wound healing and increase the risk of bleeding.

Lenshil 4mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenshil 4mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenshil 4mg Capsule, as it can impair wound healing and increase the risk of bleeding.

Lenvalieva 4mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment.

Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenvalieva 4mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenvalieva 4mg Capsule, as it can impair wound healing and increase the risk of bleeding.

Lenvatol 10mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenvatol 10mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenvatol 10mg Capsule, as it can impair wound healing and increase the risk of bleeding.

Lenvat 4mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenvat 4mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenvat 4mg Capsule, as it can impair wound healing and increase the risk of bleeding.

Lenva 4mg capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment.

Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to lenvatinib or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenva 4mg capsule, as it can impair wound healing and increase the risk of bleeding.

Lenshil 10mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. 

Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenshil 10mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenshil 10mg Capsule, as it can impair wound healing and increase the risk of bleeding.

Lenvatol 4mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenvatol 4mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenvatol 4mg Capsule, as it can impair wound healing and increase the risk of bleeding.

Lenced 4mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenced 4mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenced 4mg Capsule, as it can impair wound healing and increase the risk of bleeding.

Lenvatinib is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Patients who have had an allergic reaction to lenvatinib or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking this medication, as it can impair wound healing and increase the risk of bleeding.

Lenvatinib was first approved by the United States Food and Drug Administration (FDA) in February 2015 for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Since then, it has received additional approvals for other indications, including the treatment of hepatocellular carcinoma (liver cancer) and renal cell carcinoma (kidney cancer).